These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8141637)

  • 41. Epoetin alfa: focus on maintaining a higher, stable, Hct. Case study of the anemic patient.
    Cohen JA; Brattich M
    ANNA J; 1997 Oct; 24(5):574-80; quiz 581. PubMed ID: 9392740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Case study of the anemic patient: epoetin alfa--focus on erythrokinetics.
    Chmielewski CM
    ANNA J; 1995 Aug; 22(4):420-3. PubMed ID: 7654091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health care outcomes case study: anemia in end-stage renal disease.
    Turco TF
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S19-23. PubMed ID: 8846242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Case management of the anemic patient. Focus on hemodynamics.
    Pugh M; Saylor G
    ANNA J; 1991 Jun; 18(3):316-7. PubMed ID: 2064457
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case management of the anemic patient: epoetin alfa--focus on compliance.
    Currier H
    ANNA J; 1993 Aug; 20(4):470-3. PubMed ID: 8368881
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Review of patients' responses to epoetin alfa therapy.
    Krantz SB
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Case management of the anemic patient. Epoetin alfa: focus on kinetic dosing.
    Keen ML
    ANNA J; 1990 Aug; 17(4):318-9. PubMed ID: 2396859
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease.
    Bommer J; Kugel M; Schoeppe W; Brunkhorst R; Samtleben W; Bramsiepe P; Scigalla P
    Contrib Nephrol; 1988; 66():85-93. PubMed ID: 3292151
    [No Abstract]   [Full Text] [Related]  

  • 49. Case study of the anemic patient: epoetin alfa--focus on iron management.
    Kirlin LF
    ANNA J; 1995 Apr; 22(2):192-5. PubMed ID: 7786067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ; Petersen J
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anemia management in pediatric dialysis patients. Case study of the anemic patient.
    Currier H
    ANNA J; 1999 Jun; 26(3):349-52. PubMed ID: 10633609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Results of a multicenter trial in patients with end-stage renal disease.
    Kühn K; Nonnast-Daniel B; Grützmacher P; Grüner J; Pfåffl W; Baldamus CA; Scigalla P
    Contrib Nephrol; 1988; 66():94-103. PubMed ID: 3292152
    [No Abstract]   [Full Text] [Related]  

  • 53. Case management of the anemic patient: epoetin alfa--focus on iron supplementation.
    Kirlin LF
    ANNA J; 1993 Dec; 20(6):678-81. PubMed ID: 8267412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epoetin alfa--focus on the geriatric patient. Case study of the anemic patient.
    Mathers T
    ANNA J; 1995 Oct; 22(5):494-7. PubMed ID: 7487195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epoetin alfa: a keystone in the treatment of the anemic patient with chronic renal failure. Proceedings of a symposium held April 27, 1989, by the Keystone Chapter of ANNA, Valley Forge, Pennsylvania.
    Binkley L; Gallagher N; Latham D; Nichols E; Prowant B
    ANNA J; 1989 Aug; 16(5):341-51. PubMed ID: 2673076
    [No Abstract]   [Full Text] [Related]  

  • 56. Managing anemia using laboratory trend analysis. Case study of the anemic patient.
    Aiello J
    ANNA J; 1999 Aug; 26(4):430-3. PubMed ID: 10838975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Administering epoetin alfa. More RBCs with fewer risks.
    Biggers PB
    Nursing; 1991 Apr; 21(4):43. PubMed ID: 2020418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.